Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|

Found 126 Matches

V18 released Simcyp files for antiretroviral drugs
V18 released Simcyp files for antiretroviral drugs

Brand Name: Invirase (hard gel); Fortovase (soft gel)

Disease: HIV

Drug Class: protease inhibitor

Version: 21

Date Updated: March 2024

The model at-a-glance

 Absorption Model

First order (different absorption parameters for each formulation)

 Volume of Distribution Details

Minimal PBPK with Vsac and Q (Method 2)

 Route of Elimination

  • CYP3A4 = 95%; Additional HLM = 5%

 Perpetrator DDI

  • CYP3A4 Mechanism Based Inhibition

 Validation

The exposure of 1000mg BID saquinavir with 100 mg BID ritonavir regimen for hard gel were reasonably well recovered (3/3 within 2-fold). With the exception of the 1000 mg BID saquinavir with 100 mg BID ritonavir regimen for soft gel, the exposures of ritonavir-boosted regimens were well recovered (4/5 within 1.5-fold).

Ten clinical DDI studies where saquinavir (soft gel) was administered with either ritonavir, cimetidine, ketoconazole, rifampin, erythromycin, or rifabutin were used to verify the PBPK model of saquinavir as a victim. In comparison of predicted vs. observed AUC, 80% of the studies were within 2-fold.

Two clinical DDI studies where saquinavir (hard gel) was administered with either ritonavir or nelfinavir were used to verify the PBPK model of saquinavir (hard gel) as a victim. In comparison of predicted vs. observed AUC, 50% of the studies were within 2-fold.

Three clinical DDI studies where saquinavir was administered with either midazolam or rifabutin were used to verify the PBPK model of rifabutin (soft gel) as a perpetrator. In comparison of predicted vs. observed AUC, 100% of the studies were within 2-fold.

 Limitations

  • The variability within studies has presented a significant challenge to developing a single model to recover all data.
Simcyp_Theophylline_V21R1_Simcyp_20220614
Theophylline Pharmacokinetics Using Virtual Non-Pregnant, Pregnant, Fetal, Breast-Feeding, and Neonatal Populations
SouthAfricanTB_Population_V15R1_CPTR_20170308
.

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|